254 related articles for article (PubMed ID: 10802503)
1. Iatrogenic exposure to mercury after hepatitis B vaccination in preterm infants.
Stajich GV; Lopez GP; Harry SW; Sexson WR
J Pediatr; 2000 May; 136(5):679-81. PubMed ID: 10802503
[TBL] [Abstract][Full Text] [Related]
2. Perinatal hepatitis B transmission and vaccination timing in a managed care cohort: assessment of the temporary delay in newborn hepatitis B vaccination due to thimerosal content.
Chang S; Begier EM; Schech SD; Venus P; Shatin D; Braun MM; Ball R
Pediatr Infect Dis J; 2007 Apr; 26(4):329-33. PubMed ID: 17414397
[TBL] [Abstract][Full Text] [Related]
3. Neonate exposure to thimerosal mercury from hepatitis B vaccines.
Dórea JG; Marques RC; Brandão KG
Am J Perinatol; 2009 Aug; 26(7):523-7. PubMed ID: 19283656
[TBL] [Abstract][Full Text] [Related]
4. Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines.
Pichichero ME; Gentile A; Giglio N; Umido V; Clarkson T; Cernichiari E; Zareba G; Gotelli C; Gotelli M; Yan L; Treanor J
Pediatrics; 2008 Feb; 121(2):e208-14. PubMed ID: 18245396
[TBL] [Abstract][Full Text] [Related]
5. Impact of the 1999 AAP/USPHS joint statement on thimerosal in vaccines on infant hepatitis B vaccination practices.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Feb; 50(6):94-7. PubMed ID: 11263794
[TBL] [Abstract][Full Text] [Related]
6. Effect of thimerosal recommendations on hospitals' neonatal hepatitis B vaccination policies.
Brayden RM; Pearson KA; Jones JS; Renfrew BL; Berman S
J Pediatr; 2001 May; 138(5):752-5. PubMed ID: 11343056
[TBL] [Abstract][Full Text] [Related]
7. Early mercury exposure (with ethylmercury) could include 3-day olds: is that the case in China?
Dórea JG
Environ Res; 2008 Mar; 106(3):420; discussion 421-2. PubMed ID: 18221937
[No Abstract] [Full Text] [Related]
8. The evidence for the safety of thiomersal in newborn and infant vaccines.
Clements CJ
Vaccine; 2004 May; 22(15-16):1854-61. PubMed ID: 15121295
[TBL] [Abstract][Full Text] [Related]
9. Time of perinatal immunization, thimerosal exposure and neurodevelopment at 6 months in breastfed infants.
Marques RC; Dórea JG; Manzatto AG; Bastos WR; Bernardi JV; Malm O
Acta Paediatr; 2007 Jun; 96(6):864-8. PubMed ID: 17465985
[TBL] [Abstract][Full Text] [Related]
10. [Premature infants and hepatitis B vaccination. Study Group Prevention Neonatal Hepatitis B].
Del Canho R; Grosheide PM; Gerards LJ; Heijtink RA; Schalm SW
Tijdschr Kindergeneeskd; 1992 Aug; 60(4):105-11. PubMed ID: 1440551
[TBL] [Abstract][Full Text] [Related]
11. [Mercury in vaccines].
Hessel L
Bull Acad Natl Med; 2003; 187(8):1501-10. PubMed ID: 15146581
[TBL] [Abstract][Full Text] [Related]
12. Inactivated influenza vaccine (IIV) in children <2 years of age: examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosal-free or thimerosal-containing vaccine.
McMahon AW; Iskander JK; Haber P; Braun MM; Ball R
Vaccine; 2008 Jan; 26(3):427-9. PubMed ID: 18093701
[TBL] [Abstract][Full Text] [Related]
13. Update: expanded availability of thimerosal preservative-free hepatitis B vaccine.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2000 Jul; 49(28):642, 651. PubMed ID: 10926308
[TBL] [Abstract][Full Text] [Related]
14. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United kingdom does not support a causal association.
Heron J; Golding J;
Pediatrics; 2004 Sep; 114(3):577-83. PubMed ID: 15342824
[TBL] [Abstract][Full Text] [Related]
15. Impact of the Joint Statement by the American Academy of Pediatrics/US Public Health Service on thimerosal in vaccines on hospital infant hepatitis B vaccination practices.
Hurie MB; Saari TN; Davis JP
Pediatrics; 2001 Apr; 107(4):755-8. PubMed ID: 11335754
[TBL] [Abstract][Full Text] [Related]
16. Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines.
Rooney JP
Pediatrics; 2008 Oct; 122(4):902; author reply 902-3. PubMed ID: 18829819
[No Abstract] [Full Text] [Related]
17. Exposure to thimerosal in vaccines used in Canadian infant immunization programs, with respect to risk of neurodevelopmental disorders.
Bigham M; Copes R; Srour L
Can Commun Dis Rep; 2002 May; 28(9):69-80. PubMed ID: 12012653
[No Abstract] [Full Text] [Related]
18. Neuropsychological performance 10 years after immunization in infancy with thimerosal-containing vaccines.
Tozzi AE; Bisiacchi P; Tarantino V; De Mei B; D'Elia L; Chiarotti F; Salmaso S
Pediatrics; 2009 Feb; 123(2):475-82. PubMed ID: 19171612
[TBL] [Abstract][Full Text] [Related]
19. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association.
Andrews N; Miller E; Grant A; Stowe J; Osborne V; Taylor B
Pediatrics; 2004 Sep; 114(3):584-91. PubMed ID: 15342825
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B vaccine coverage among infants born to women without prenatal screening for hepatitis B virus infection: effects of the Joint Statement on Thimerosal in Vaccines.
Thomas AR; Fiore AE; Corwith HL; Cieslak PR; Margolis HS
Pediatr Infect Dis J; 2004 Apr; 23(4):313-8. PubMed ID: 15071284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
